Okyanos Heart Institute Names New Chief Cell Therapy Officer
Okyanos Heart Institute has announced the addition of Dr. Todd Malan to their executive medical team as Chief Cell Therapy Officer and General Surgeon. He will perform and oversee the liposuction step of Okyanos treatment, removing a small amount of fat from patients from which their own stem cells are isolated. Cardiac cell therapy is intended for no-option heart patients who have exhausted the currently available standards of care for their condition, of which there are about 2 million in the United States alone.
Dr. Malan is founder of the Innovative Cosmetic Surgery Center in Scottsdale, Arizona, specializing in advanced liposuction and fat transfer procedures. A pioneer in adipose- (fat) derived stem cell research and fellow of the American Academy of Cosmetic Surgery, Dr. Malan became the first physician in the United States to utilize adult stem cells from fat tissue for soft tissue reconstruction. He has co-authored two medical textbooks on fat-derived stem cell therapies and has served as principal investigator on two Institutional Review Board- (IRB) approved adult stem cell trials.
“As an active member of the adipose stem cell research community, Dr. Malan is very familiar with the therapeutic benefits of adult stem cells for cardiac, as demonstrated in clinical trials,” said Dr. Howard Walpole, chief medical officer at Okyanos. “He lends his experience and integrated knowledge of both innovative cosmetic surgery and stem cell therapy to our medical leadership team,” he added.
“It is truly gratifying to see the gathering of like-minded researchers, clinicians, and administrators who see the remarkable value of developing evidence-based protocols for effective stem cell therapies,” said Dr. Malan. He added, “This project is a culmination of years of experience between industry leaders who are dedicated to making Okyanos a premier cell therapy center in the world. The work we do today will define the future of medicine for years to come.”
Okyanos cardiac cell therapy is the first stem cell-based procedure for heart failure available to patients outside of clinical trials, wherein the patient’s own adipose-derived stem cells are infused directly into the damaged part of the heart via catheter. Okyanos will begin treating advanced heart disease patients in Freeport, The Bahamas, in the summer of 2014.
ABOUT OKYANOS HEART INSTITUTE: [Oh – key – AH – nos]
Based in Freeport, The Bahamas, Okyanos Heart Institute’s mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by founder and CEO Matt Feshbach, as well as Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.S.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from one’s own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive procedure, can stimulate the growth of new blood vessels, a process known as angiogenesis. Angiogenesis facilitates blood flow in the heart, which supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos, the Greek god of rivers, symbolizes restoration of blood flow.
For more information, please visit www.okyanos.com